Tribuzone

Tribuzone

SCHEMBL2109159

CC(C)(C)C(=O)CCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
CYP3A4 P08684 2/20 0.52
LMNA P02545 2/20 0.52
PTGS1 P23219 2/20 0.52
MAPT P10636 2/20 0.52
CYP1A2 P05177 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
MAPK1 P28482 1/20 0.52
TP53 P04637 1/20 0.52
HPGD P15428 1/20 0.52
RAB9A P51151 1/20 0.52
NAPRT Q6XQN6 1/20 0.52
ABCB11 O95342 1/20 0.50
HSD11B1 P28845 4/20 0.37
MT-CO2 P00403 2/20 0.37
ALOX5 P09917 2/20 0.37
ATM Q13315 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
CES2 O00748 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11327437 0.93 ALDH1A1 (0.64) ALDH1A1CYP3A4LMNAPTGS1MAPT
SCHEMBL11327797 0.90 ALDH1A1 (0.51) ALDH1A1CYP3A4LMNAPTGS1MAPT
SCHEMBL11322746 0.87 ALDH1A1 (0.49) ALDH1A1CYP3A4LMNAPTGS1MAPT
Kebuzone SCHEMBL231224 0.83 LMNA (0.58) ALDH1A1CYP3A4LMNAPTGS1MAPT
SCHEMBL11324940 0.82 MAPT (0.50) ALDH1A1CYP3A4LMNAPTGS1MAPT
Kebuzone SCHEMBL6375816 0.81 LMNA (0.56) ALDH1A1CYP3A4LMNAPTGS1MAPT
SCHEMBL11329439 0.80 ALDH1A1 (0.57) ALDH1A1CYP3A4LMNAPTGS1MAPT
SCHEMBL11321102 0.79 ALDH1A1 (0.52) ALDH1A1CYP3A4LMNAPTGS1MAPT
SCHEMBL11332855 0.78 CYP3A4 (0.51) ALDH1A1CYP3A4LMNAPTGS1MAPT
SCHEMBL28552048 0.78 LMNA (0.56) ALDH1A1CYP3A4LMNAPTGS1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4714928-A1 A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A HETEROCYCLIC COMPOUND COMPRISING AT LEAST ONE N-N SINGLE BOND Hilti Aktiengesellschaft (LI) 2026-03-25 EP claimed
US-20240269115-A1 PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES FLONEXT S.R.L. (IT) 2024-08-15 US claimed
EP-4351571-A1 PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES Flonext S.r.l. (IT) 2024-04-17 EP claimed
WO-2022259132-A1 PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES FLONEXT S.R.L. (IT) 2022-12-15 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
WO-2013020527-A1 UTILIZATION OF ALAPTIDE AS TRANSDERMAL PENETRATION MODIFIER IN PHARMACEUTICAL COMPOSITIONS FOR HUMAN AND VETERINARY APPLICATIONS CONTAINING ANTI-INFLAMMATORY DRUGS AND/OR ANTIMICROBIAL CHEMOTHERAPEUTICS UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES BRNO FACULTY OF PHARMACY (CZ) 2013-02-14 WO claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-4447988-B1 COMPOSITIONS FOR TREATING AUTOIMMUNE ARTHRITIS DEVINTEC SAGL (CH) 2026-05-27 EP disclosed
EP-4735462-A1 COMPOUNDS AND USES THEREFOR GLYCOSYNNOVATIONS PTY LTD (AU) 2026-05-06 EP disclosed
EP-4735463-A1 COMPOUNDS AND USES THEREFOR GLYCOSYNNOVATIONS PTY LTD (AU) 2026-05-06 EP disclosed
EP-4725478-A2 RAPIDLY INFUSING PLATFORM AND COMPOSITIONS FOR THERAPEUTIC TREATMENT IN HUMANS Orcosa Inc. (US) 2026-04-15 EP disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
US-4273873-A BONDING SYNTHETIC FIBRINOLYTIC COMPOUND OR ENZYME UNITIKA LTD. (JP) 1981-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240269115-A1 PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES ALDH1A2, PDK3, EYA3 ALDH1A1 241/4885CYP3A4 2539/4885LMNA 788/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 ALDH1A1 4459/4885CYP3A4 4863/4885LMNA 1552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.